A BOOSTER shot of the anti-Covid-19 vaccine developed by Pfizer/BioNTech is 95.6% effective against symptomatic infection, according to trial data published by the makers recently.
ALSO READ: How to identify and fight Covid-19 misinformation on social media
The clinical phase three trial with “10,000 participants 16 years of age and older” showed “a relative vaccine efficacy of 95.6 percent against disease during a period when Delta was the prevalent strain”, the companies said in a statement. The study presented the “first results” of a booster trial, with a third shot of the vaccine demonstrating a “favourable safety profile”.
“These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,” said Pfizer CEO Albert Bourla.
Several countries have already approved Covid-19 booster shots to increase immunity in people who have already been vaccinated, but whose protection may have dipped after several months, per some studies. In the United States, the federal Food and Drug Administration (FDA) approved a third dose in September for everyone aged 65 and up, as well as people at high risk of developing severe Covid. The European Medicines Agency (EMA) approved a booster for over-18s at the beginning of October, allowing national regulators to decide which groups should be eligible first. In Israel, authorities have gone further, approving booster shots for everyone aged 12 and over.
DID YOU KNOW?
Click on the words highlighted in red to read more on this and related topics. To receive news links via WhatsApp or Telegram, send an invite to 061 694 6047.
The South Coast Sun is also on Facebook, Twitter, Instagram– why not join us there?
Do you have more information pertaining to this story?
Feel free to let us know by commenting on our Facebook page or you can contact our newsroom on 031 903 2341 and speak to a journalist.
(Comments posted on this issue may be used for publication in the Sun)
